Immunologic and virologic evolution during periods of intermittent and persistent low-level viremia.
about
Impact of low-level-viremia on HIV-1 drug-resistance evolution among antiretroviral treated-patientsAppraising Viral Load Thresholds and Adherence Support Recommendations in the World Health Organization Guidelines for Detection and Management of Virologic Failure.Characterizing Patients with Very-Low-Level HIV Viremia: A Community-Based StudyAbility of two commercially available assays (Abbott RealTime HIV-1 and Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 Version 2.0) to quantify low HIV-1 RNA Levels (<1,000 copies/milliliter): comparison with clinical samples and NIBSC working reagent forLimited evolution of inferred HIV-1 tropism while viremia is undetectable during standard HAART therapyImmunological and virological characterization of HIV-1 viremia controllers in the North Region of Brazil.Significance and clinical management of persistent low-level viremia and very-low-level viremia in HIV-1-infected patients.Virological failure and all-cause mortality in HIV-positive adults with low-level viremia during antiretroviral treatment.The significance of low-level viraemia in diverse settings: analysis of the Treat Asia HIV Observational Database (TAHOD) and the Australian HIV Observational Database (AHOD).Phylogenetic evidence of HIV-1 sequence evolution in subjects with persistent low-level viraemia.Increased risk of virologic rebound in patients on antiviral therapy with a detectable HIV load <48 copies/mLHIV drug resistance detected during low-level viraemia is associated with subsequent virologic failureDetection of nonnucleoside reverse-transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy.HIV Drug Resistance Profiles and Clinical Outcomes in Patients with Viremia Maintained at Very Low Levels.HIV controllers with different viral load cutoff levels have distinct virologic and immunologic profiles.Antiretroviral regimen and suboptimal medication adherence are associated with low-level human immunodeficiency virus viremia.Antiretroviral drug resistance in HIV-1-infected patients experiencing persistent low-level viremia during first-line therapyHIV Replication at Low Copy Number and its Correlation with the HIV Reservoir: A Clinical Perspective.Evaluation of antiretroviral therapy results in Blantyre, Malawi.Predicting resistance as indicator for need to switch from first-line antiretroviral therapy among patients with elevated viral loads: development of a risk score algorithmDifferential effects of viremia and microbial translocation on immune activation in HIV-infected patients throughout ritonavir-boosted darunavir monotherapy.Interleukin 10 responses are associated with sustained CD4 T-cell counts in treated HIV infectionInfluence of episodes of intermittent viremia ("blips") on immune responses and viral load rebound in successfully treated HIV-infected patients.CD8+ T-cell activation in HIV-1-infected patients experiencing transient low-level viremia during antiretroviral therapyFrequent Episodes of Detectable Viremia in HIV Treatment-Experienced Children is Associated with a Decline in CD4+ T-cells Over Time.Development and evaluation of a clinical algorithm to monitor patients on antiretrovirals in resource-limited settings using adherence, clinical and CD4 cell count criteria.Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir.Hepatitis B vaccine responses in a large U.S. military cohort of HIV-infected individuals: another benefit of HAART in those with preserved CD4 count.HIV type 1 viremia on ART is positively associated with polyclonal T cell proliferation in subjects with T cell IFN-gamma secretion levels comparable to those of uninfected subjectsLow-level viremia in HIV-1 infection: consequences and implications for switching to a new regimen.Causes and consequences of incomplete HIV RNA suppression in clinical trials.Performance of HIV-1 drug resistance testing at low-level viremia and its ability to predict future virologic outcomes and viral evolution in treatment-naive individuals.Counter-intuitive plasma vitamin D and zinc status in HIV-1-infected adults with persistent low-level viraemia after treatment initiation: a pilot case-control study.Time to Viremia for Patients Taking their First Antiretroviral Regimen and the Subsequent Resistance Profiles.Expression of gut-homing β7 receptor on T cells: surrogate marker for microbial translocation in suppressed HIV-1-infected patients?Rate of and predicting factors for virologic failure in HIV-infected patients with persistent low-level viremia under antiretroviral therapy.Virologic failure following persistent low-level viremia in a cohort of HIV-positive patients: results from 12 years of observation.Efficacy, safety, and tolerability of long-term combination antiretroviral therapy in asymptomatic treatment-naïve adults with early HIV infection.Persistent low-level viremia in HIV-1 elite controllers and relationship to immunologic parameters.Anti-human immunodeficiency virus type 1 humoral immune response and highly active antiretroviral treatment.
P2860
Q28483630-6EE715DD-38F7-4A35-A1A6-07D158F54EDFQ30492033-BD208D50-48BE-4104-98DA-2219000806C0Q33653518-24C31E7A-1F50-45A3-B8F2-0CB18751D6C5Q33703537-35E0E094-B98B-4E20-BD32-4E12EC38306FQ33721466-1ADDE5D1-96A4-453D-961A-7B533B1E2651Q33755753-583F258E-B164-4B14-B456-8B8B6609A8D1Q33798584-7AE63879-BDCF-46A4-891F-B8472488007AQ33880782-BA2EC70B-9E9C-47C8-B5D4-F480FB622AFDQ33934935-3EAA6882-6960-43C2-94FF-BE27236FC32FQ34289476-2FC1EEA2-411D-481A-A947-8BED794319BEQ34482990-98B91A0F-49C6-4BBA-8B86-C52624909E28Q34781706-4BF0FA27-9293-4404-9A50-FED3EA982B8FQ34786892-BD95707F-C6F6-43A9-AED9-99762368CABFQ35057427-7D8ECFD6-E336-421F-A90A-549C5B12BCFBQ35102172-7EFE6D6C-633D-4718-903A-F11BC5C08A44Q35408114-E5F138B4-C1F0-46A3-A5EB-8A056A3EDB7FQ35466014-627A37C1-D785-414B-8FB6-2E3392A53A3FQ35698144-750F829D-551C-4BDD-984C-154D93E13C05Q35937624-C3A508EB-C270-45C8-A21E-6E42D276C3B8Q36050916-90E61669-B188-4764-B632-CB345B281329Q36153849-1352B7E3-2224-45D1-8571-2C96D2B873DEQ36379299-CCEEB2CE-EADD-4D27-AA3D-7B40A08F654DQ36509570-2FA8049B-3A61-4CD2-9321-28CA15C70C6EQ36784163-7FE53C06-12E8-4CCE-ACA7-CECB2015DB28Q37057964-6FF06842-DB0E-40C1-8F7B-DA7EB3600D4BQ37147686-FBDB2DE9-E0D0-42BB-9FFA-61E775682A0DQ37235740-E3A3F280-FE85-4865-A921-23B95D5F7CB2Q37254537-7C281944-D175-4F52-B16F-81701C31C7BCQ37388340-B70C6D38-C99B-4A81-AEEA-FF015A887886Q37504245-1105E41A-BD5C-4D52-866C-C3803E1DCC44Q37631282-4D77BF97-DB1F-46CF-AA52-79341A10392DQ37668850-506008C0-78A9-44A9-80E6-47EE2CB56837Q40146615-8CFB955A-103A-4AC4-87CC-ACBF7E6563D5Q40783234-8094AAE7-6595-4B26-A3C6-F3FFA136F24FQ42215126-0033A01E-8BC0-4B39-A644-4687CE8F8ABFQ42230066-AD3668CC-1B0E-4BB8-84B1-AE486094052FQ42276682-37D8D30F-0B60-4728-8821-4E2FE0D815C0Q42635373-556BF378-D028-40B8-AEA3-E68CDBD04A47Q43070781-D4CF815A-D46F-4099-8F6A-2CB99E970661Q43750850-A502E2B4-8EF1-4614-8FCB-C4FFD6E8ACCD
P2860
Immunologic and virologic evolution during periods of intermittent and persistent low-level viremia.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Immunologic and virologic evol ...... persistent low-level viremia.
@en
Immunologic and virologic evol ...... persistent low-level viremia.
@nl
type
label
Immunologic and virologic evol ...... persistent low-level viremia.
@en
Immunologic and virologic evol ...... persistent low-level viremia.
@nl
prefLabel
Immunologic and virologic evol ...... persistent low-level viremia.
@en
Immunologic and virologic evol ...... persistent low-level viremia.
@nl
P2093
P1433
P1476
Immunologic and virologic evol ...... persistent low-level viremia.
@en
P2093
Annika C Karlsson
Elilta Hagos
Elizabeth Sinclair
Jeffrey N Martin
Peter W Hunt
Sophie R Younger
Zvi Grossman
P304
P356
10.1097/00002030-200404300-00005
P407
P577
2004-04-01T00:00:00Z